Literature DB >> 16895639

Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study.

Judith A F Huirne1, Andre C D van Loenen, Jacques Donnez, Céline Pirard, Roy Homburg, Roel Schats, Joseph McDonnell, Cornelis B Lambalk.   

Abstract

This randomized controlled study compared the effectiveness of a gonadotrophin releasing hormone (GnRH) antagonist protocol with or without oral contraceptive (OC) pretreatment on the number of oocytes retrieved in IVF or intracytoplasmic sperm injection (ICSI) patients. Sixty-four patients were randomized to start recombinant human FSH (r-hFSH) on day 2 or 3 after OC withdrawal (OC group) or on day 2 of a natural cycle (control group). From stimulation day 6 onwards, all patients were treated with daily (0.5 mg/ml) GnRH antagonist (Antide). OC pretreatment resulted in significantly lower starting concentrations of FSH, LH and oestradiol (P < 0.001) and a thinner endometrium (P < 0.0001). In the early stimulation period, fewer large follicles were found after OC pretreatment, leading to a significantly extended stimulation period (11.6 versus 8.7 days, P < 0.0001) with more follicles on the day of recombinant human chorionic gonadotrophin administration (15.4 versus 12.5, P = 0.02) and more oocytes retrieved (13.5 versus 10.2, P < 0.001) as compared with the control group. GnRH antagonist regimen, pretreated with OC, prevented the early endogenous FSH rise and improved follicular homogeneity, resulting in more oocytes. As a consequence of the extended treatment period, more rhFSH was required.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16895639     DOI: 10.1016/s1472-6483(10)60621-9

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  7 in total

1.  Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles.

Authors:  M N Kalem; Z Kalem; T Gurgan
Journal:  J Endocrinol Invest       Date:  2017-02-27       Impact factor: 4.256

2.  Early gonadotropin-releasing hormone antagonist start improves follicular synchronization and pregnancy outcome as compared to the conventional antagonist protocol.

Authors:  Chan Woo Park; Yu Im Hwang; Hwa Seon Koo; Inn Soo Kang; Kwang Moon Yang; In Ok Song
Journal:  Clin Exp Reprod Med       Date:  2014-12-31

3.  Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome.

Authors:  Daimin Wei; Yuhua Shi; Jing Li; Ze Wang; Lin Zhang; Yun Sun; Hong Zhou; Yuping Xu; Chunxiang Wu; Ling Liu; Qiongfang Wu; Lili Zhuang; Yanzhi Du; Weiping Li; Heping Zhang; Richard S Legro; Zi-Jiang Chen
Journal:  Hum Reprod       Date:  2016-12-19       Impact factor: 6.918

4.  The effect of oral contraceptive pill for cycle scheduling prior to GnRH-antagonist protocol on IVF cycle parameters and pregnancy outcome.

Authors:  Haim Pinkas; Onit Sapir; Ori M Avrech; Avi Ben-Haroush; Jacob Ashkenzi; Benjamin Fisch; Jacob Farhi
Journal:  J Assist Reprod Genet       Date:  2008-01-19       Impact factor: 3.412

5.  Estradiol Valerate Pretreatment in Short Protocol GnRH-Agonist Cycles versus Combined Pretreatment with Oral Contraceptive Pills in Long Protocol GnRH-Agonist Cycles: A Randomised Controlled Trial.

Authors:  Krzysztof Lukaszuk; Joanna Liss; Michal Kunicki; Waldemar Kuczynski; Ewa Pastuszek; Grzegorz Jakiel; Lukasz Plociennik; Krzysztof Zielinski; Judyta Zabielska
Journal:  Biomed Res Int       Date:  2015-04-02       Impact factor: 3.411

6.  Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis.

Authors:  Sally Kadoura; Marwan Alhalabi; Abdul Hakim Nattouf
Journal:  Sci Rep       Date:  2022-03-15       Impact factor: 4.379

Review 7.  Optimal usage of the GnRH antagonists: a review of the literature.

Authors:  Alan B Copperman; Claudio Benadiva
Journal:  Reprod Biol Endocrinol       Date:  2013-03-15       Impact factor: 5.211

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.